Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind comparison of recombinant anti-RANKL monoclonal antibody injection versus Prolia in Chinese postmenopausal women with osteoporosis at high fracture risk
CTR20243829Phase 3Active
- Sponsor
- Jiangsu Pacific Meinuoke Biopharmaceutical
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of denosumab, G201702 in postmenopausal osteoporosis, sponsored by Jiangsu Pacific Meinuoke Biopharmaceutical. Started Dec 2024; status: active.
02
Drugs
denosumabG201702
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on CTR20243829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243829.